|
1
|
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
|
J Clin Oncol
|
2003
|
15.10
|
|
2
|
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
|
Lancet Oncol
|
2010
|
8.56
|
|
3
|
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
|
J Clin Oncol
|
2004
|
8.15
|
|
4
|
Targeting the dynamic HSP90 complex in cancer.
|
Nat Rev Cancer
|
2010
|
6.81
|
|
5
|
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
4.95
|
|
6
|
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
|
J Natl Cancer Inst
|
2007
|
4.40
|
|
7
|
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
|
J Clin Oncol
|
2005
|
4.04
|
|
8
|
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
|
Lancet Oncol
|
2013
|
4.04
|
|
9
|
Cell death independent of caspases: a review.
|
Clin Cancer Res
|
2005
|
3.85
|
|
10
|
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
|
J Clin Oncol
|
2011
|
3.73
|
|
11
|
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
|
J Thorac Oncol
|
2013
|
3.71
|
|
12
|
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
|
Clin Cancer Res
|
2009
|
3.65
|
|
13
|
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.
|
J Clin Oncol
|
2011
|
3.21
|
|
14
|
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
|
J Natl Cancer Inst
|
2003
|
2.95
|
|
15
|
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
|
J Mol Diagn
|
2013
|
2.71
|
|
16
|
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
|
Arch Pathol Lab Med
|
2013
|
2.66
|
|
17
|
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
|
J Clin Oncol
|
2003
|
2.62
|
|
18
|
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
|
J Clin Oncol
|
2002
|
2.55
|
|
19
|
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
|
J Clin Oncol
|
2008
|
2.51
|
|
20
|
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
|
Clin Cancer Res
|
2003
|
2.44
|
|
21
|
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
|
J Clin Oncol
|
2006
|
2.33
|
|
22
|
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
|
Clin Cancer Res
|
2012
|
2.26
|
|
23
|
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
|
J Clin Oncol
|
2002
|
2.18
|
|
24
|
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
|
J Clin Oncol
|
2005
|
2.15
|
|
25
|
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.
|
Clin Cancer Res
|
2009
|
2.03
|
|
26
|
Apoptosis: target of cancer therapy.
|
Clin Cancer Res
|
2002
|
1.99
|
|
27
|
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer.
|
Proc Natl Acad Sci U S A
|
2012
|
1.97
|
|
28
|
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
|
PLoS One
|
2010
|
1.96
|
|
29
|
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.
|
Cancer Res
|
2010
|
1.89
|
|
30
|
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
|
J Clin Oncol
|
2002
|
1.72
|
|
31
|
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
|
Eur J Cancer
|
2008
|
1.70
|
|
32
|
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
|
Int J Cancer
|
2006
|
1.67
|
|
33
|
Global histone modifications predict prognosis of resected non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
1.60
|
|
34
|
Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia.
|
Blood
|
2010
|
1.56
|
|
35
|
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.
|
J Thorac Oncol
|
2014
|
1.56
|
|
36
|
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection.
|
J Immunol
|
2002
|
1.52
|
|
37
|
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
|
J Clin Oncol
|
2006
|
1.52
|
|
38
|
EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens.
|
Cell Oncol
|
2007
|
1.48
|
|
39
|
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
|
Proc Natl Acad Sci U S A
|
2010
|
1.45
|
|
40
|
Histone deacetylase inhibitors in cancer therapy.
|
Curr Opin Oncol
|
2008
|
1.44
|
|
41
|
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin.
|
Exp Cell Res
|
2002
|
1.44
|
|
42
|
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973).
|
Eur J Cancer
|
2006
|
1.43
|
|
43
|
How should we analyse FDG PET studies for monitoring tumour response?
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.41
|
|
44
|
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
|
Eur J Cancer
|
2007
|
1.38
|
|
45
|
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
|
Mol Pharmacol
|
2008
|
1.37
|
|
46
|
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
|
Eur J Nucl Med Mol Imaging
|
2008
|
1.36
|
|
47
|
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
|
Eur J Cancer
|
2009
|
1.36
|
|
48
|
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
|
Clin Cancer Res
|
2008
|
1.36
|
|
49
|
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
|
Mol Cancer Ther
|
2007
|
1.34
|
|
50
|
Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells.
|
Cancer Res
|
2004
|
1.34
|
|
51
|
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
|
BMC Cancer
|
2006
|
1.33
|
|
52
|
Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres.
|
Mol Biol Cell
|
2006
|
1.33
|
|
53
|
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
|
Cancer
|
2005
|
1.32
|
|
54
|
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
|
Clin Cancer Res
|
2006
|
1.30
|
|
55
|
Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.
|
Mol Pharmacol
|
2005
|
1.30
|
|
56
|
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
|
Mol Cancer Ther
|
2006
|
1.28
|
|
57
|
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
|
Curr Opin Investig Drugs
|
2010
|
1.27
|
|
58
|
Thymic malignancies: from clinical management to targeted therapies.
|
J Clin Oncol
|
2011
|
1.25
|
|
59
|
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
|
Clin Cancer Res
|
2012
|
1.23
|
|
60
|
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
|
J Exp Clin Cancer Res
|
2010
|
1.23
|
|
61
|
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
|
Eur J Cancer
|
2007
|
1.21
|
|
62
|
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
|
Clin Cancer Res
|
2012
|
1.21
|
|
63
|
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.
|
J Thorac Oncol
|
2014
|
1.21
|
|
64
|
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
|
Br J Clin Pharmacol
|
2011
|
1.20
|
|
65
|
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.
|
BMC Cancer
|
2009
|
1.20
|
|
66
|
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
|
Clin Cancer Res
|
2011
|
1.20
|
|
67
|
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.
|
J Oncol Pract
|
2011
|
1.16
|
|
68
|
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
|
Clin Cancer Res
|
2011
|
1.16
|
|
69
|
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
|
Cancer
|
2014
|
1.15
|
|
70
|
Expression and mutational status of c-kit in thymic epithelial tumors.
|
J Thorac Oncol
|
2010
|
1.15
|
|
71
|
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.
|
PLoS One
|
2008
|
1.14
|
|
72
|
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors.
|
J Thorac Oncol
|
2014
|
1.12
|
|
73
|
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2010
|
1.12
|
|
74
|
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
|
Mol Cancer Ther
|
2007
|
1.11
|
|
75
|
Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS.
|
Proteomics Clin Appl
|
2007
|
1.10
|
|
76
|
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460.
|
Clin Cancer Res
|
2002
|
1.08
|
|
77
|
Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2.
|
Exp Cell Res
|
2004
|
1.08
|
|
78
|
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
|
Mod Pathol
|
2011
|
1.07
|
|
79
|
The immunoregulatory role of CD1d-restricted natural killer T cells in disease.
|
Clin Immunol
|
2004
|
1.06
|
|
80
|
Expression and localization of inhibitor of apoptosis proteins in normal human tissues.
|
Hum Pathol
|
2005
|
1.05
|
|
81
|
Treatment of advanced thymoma and thymic carcinoma.
|
Curr Treat Options Oncol
|
2009
|
1.04
|
|
82
|
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.
|
Cancer
|
2010
|
1.04
|
|
83
|
Homodimerization antagonizes nuclear export of survivin.
|
Traffic
|
2007
|
1.04
|
|
84
|
Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies.
|
Int J Cancer
|
2005
|
1.03
|
|
85
|
The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies.
|
J Thorac Oncol
|
2013
|
1.00
|
|
86
|
Biology and management of malignant pleural mesothelioma.
|
Eur J Cancer
|
2006
|
1.00
|
|
87
|
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.
|
Eur Radiol
|
2006
|
1.00
|
|
88
|
MicroRNA expression and clinical outcome of small cell lung cancer.
|
PLoS One
|
2011
|
0.99
|
|
89
|
Targeted agents: how to select the winners in preclinical and early clinical studies?
|
Eur J Cancer
|
2011
|
0.99
|
|
90
|
Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
|
Cancer Res
|
2003
|
0.99
|
|
91
|
EGFR inhibitors in lung cancer.
|
Oncology (Williston Park)
|
2005
|
0.98
|
|
92
|
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
|
J Thorac Oncol
|
2014
|
0.98
|
|
93
|
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors.
|
J Thorac Oncol
|
2014
|
0.98
|
|
94
|
Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.
|
J Clin Oncol
|
2010
|
0.96
|
|
95
|
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.
|
J Mol Med (Berl)
|
2014
|
0.96
|
|
96
|
Role and relevance of TrkB mutations and expression in non-small cell lung cancer.
|
Clin Cancer Res
|
2011
|
0.96
|
|
97
|
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.
|
Proc Natl Acad Sci U S A
|
2012
|
0.96
|
|
98
|
Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years.
|
J Clin Endocrinol Metab
|
2012
|
0.95
|
|
99
|
Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
|
Eur J Pharmacol
|
2010
|
0.95
|
|
100
|
Angiogenesis inhibitors. Drug selectivity and target specificity.
|
Curr Pharm Des
|
2007
|
0.95
|
|
101
|
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
|
Cell Cycle
|
2011
|
0.95
|
|
102
|
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
|
Clin Cancer Res
|
2007
|
0.95
|
|
103
|
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
|
J Clin Invest
|
2014
|
0.95
|
|
104
|
The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer.
|
Curr Opin Investig Drugs
|
2009
|
0.95
|
|
105
|
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
|
J Thorac Oncol
|
2006
|
0.95
|
|
106
|
Small-molecule inhibitors of the human epidermal receptor family.
|
Expert Opin Investig Drugs
|
2009
|
0.94
|
|
107
|
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
|
J Nucl Med
|
2009
|
0.93
|
|
108
|
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
|
Mol Cancer Ther
|
2010
|
0.93
|
|
109
|
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
|
Eur J Cancer
|
2010
|
0.93
|
|
110
|
The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression.
|
Oncogene
|
2004
|
0.93
|
|
111
|
Next generation oncology drug development: opportunities and challenges.
|
Nat Rev Clin Oncol
|
2009
|
0.93
|
|
112
|
A population-based assessment of mortality and morbidity patterns among patients with thymoma.
|
Int J Cancer
|
2010
|
0.93
|
|
113
|
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.
|
Anticancer Drugs
|
2007
|
0.92
|
|
114
|
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
|
Mol Cancer Ther
|
2013
|
0.91
|
|
115
|
HER2 mutations in non-small-cell lung cancer can be continually targeted.
|
J Clin Oncol
|
2012
|
0.90
|
|
116
|
Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.
|
Curr Opin Oncol
|
2012
|
0.90
|
|
117
|
Characterization and management of cardiac involvement of thymic epithelial tumors.
|
J Thorac Oncol
|
2013
|
0.90
|
|
118
|
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.
|
J Oncol Pract
|
2010
|
0.90
|
|
119
|
Drug development: portals of discovery.
|
Clin Cancer Res
|
2012
|
0.90
|
|
120
|
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.
|
Mol Cancer
|
2007
|
0.90
|
|
121
|
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
|
Clin Cancer Res
|
2002
|
0.89
|
|
122
|
The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.
|
Clin Cancer Res
|
2013
|
0.89
|
|
123
|
Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
|
Cancer Res
|
2004
|
0.89
|
|
124
|
Acupuncture treatment for persistent hiccups in patients with cancer.
|
J Altern Complement Med
|
2010
|
0.89
|
|
125
|
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.
|
Lung Cancer
|
2009
|
0.89
|
|
126
|
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.
|
Clin Cancer Res
|
2011
|
0.89
|
|
127
|
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy.
|
Front Oncol
|
2013
|
0.89
|
|
128
|
Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?
|
Curr Opin Oncol
|
2005
|
0.89
|
|
129
|
Novel agents in the treatment of lung cancer: conference summary statement.
|
Clin Cancer Res
|
2004
|
0.88
|
|
130
|
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
|
Clin Lung Cancer
|
2010
|
0.88
|
|
131
|
Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export.
|
Hum Mol Genet
|
2005
|
0.88
|
|
132
|
Chemotherapy for thymic tumors: induction, consolidation, palliation.
|
Thorac Surg Clin
|
2011
|
0.87
|
|
133
|
Targeted therapy for advanced thymic tumors.
|
J Thorac Oncol
|
2010
|
0.87
|
|
134
|
Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling.
|
J Mol Diagn
|
2010
|
0.87
|
|
135
|
Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation.
|
Exp Cell Res
|
2006
|
0.87
|
|
136
|
Novel approaches to the treatment of non-small cell lung cancer.
|
Crit Rev Oncol Hematol
|
2002
|
0.86
|
|
137
|
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
|
Pharmacogenomics
|
2011
|
0.86
|
|
138
|
Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells.
|
J Proteomics
|
2008
|
0.86
|
|
139
|
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.
|
Mol Cancer
|
2007
|
0.85
|
|
140
|
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.
|
Clin Cancer Res
|
2013
|
0.84
|
|
141
|
Emerging protein kinase inhibitors for non-small cell lung cancer.
|
Expert Opin Emerg Drugs
|
2013
|
0.84
|
|
142
|
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
|
Oncologist
|
2003
|
0.84
|
|
143
|
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.
|
Clin Cancer Res
|
2005
|
0.84
|
|
144
|
Image microarrays (IMA): Digital pathology's missing tool.
|
J Pathol Inform
|
2011
|
0.84
|
|
145
|
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
|
J Thorac Oncol
|
2014
|
0.84
|
|
146
|
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.
|
Clin Cancer Res
|
2013
|
0.84
|
|
147
|
Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases.
|
J Thorac Oncol
|
2007
|
0.83
|
|
148
|
FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy.
|
Clin Lung Cancer
|
2005
|
0.83
|
|
149
|
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
|
Eur J Cancer
|
2013
|
0.83
|
|
150
|
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
0.83
|
|
151
|
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2010
|
0.82
|
|
152
|
Lung cancer vaccines.
|
Cancer J
|
2011
|
0.82
|
|
153
|
Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.
|
J Natl Cancer Inst
|
2013
|
0.82
|
|
154
|
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
|
Curr Drug Targets
|
2010
|
0.82
|
|
155
|
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
|
Clin Cancer Res
|
2011
|
0.82
|
|
156
|
Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC.
|
Int J Cancer
|
2008
|
0.81
|
|
157
|
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).
|
Lung Cancer
|
2005
|
0.81
|
|
158
|
Whole genome and transcriptome sequencing of a B3 thymoma.
|
PLoS One
|
2013
|
0.81
|
|
159
|
Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.81
|
|
160
|
Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells.
|
Cancer Res
|
2002
|
0.81
|
|
161
|
The role of new agents in the treatment of non-small cell lung cancer.
|
Eur J Cancer
|
2002
|
0.81
|
|
162
|
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
|
Clin Cancer Res
|
2007
|
0.81
|
|
163
|
The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors.
|
J Thorac Oncol
|
2014
|
0.80
|
|
164
|
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.
|
Expert Opin Pharmacother
|
2013
|
0.80
|
|
165
|
Tyrosine kinase inhibitors in lung cancer.
|
Hematol Oncol Clin North Am
|
2012
|
0.80
|
|
166
|
Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.
|
Cancer Gene Ther
|
2004
|
0.80
|
|
167
|
Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples.
|
Acta Cytol
|
2012
|
0.80
|
|
168
|
International thymic malignancy interest group.
|
J Thorac Oncol
|
2010
|
0.80
|
|
169
|
Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma.
|
J Thorac Oncol
|
2013
|
0.80
|
|
170
|
Thymoma-associated paraneoplastic polymyositis.
|
J Clin Oncol
|
2010
|
0.79
|
|
171
|
Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins.
|
Biochem J
|
2003
|
0.79
|
|
172
|
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.79
|
|
173
|
Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.
|
Int J Oncol
|
2010
|
0.79
|
|
174
|
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2010
|
0.79
|
|
175
|
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
|
Cancer Sci
|
2013
|
0.79
|
|
176
|
Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition.
|
Immunotherapy
|
2011
|
0.79
|
|
177
|
TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells.
|
BMC Cancer
|
2006
|
0.79
|
|
178
|
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
|
Oncologist
|
2013
|
0.79
|
|
179
|
Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner.
|
Exp Cell Res
|
2003
|
0.79
|
|
180
|
Population pharmacokinetics of the novel anticancer agent KRN7000.
|
Cancer Chemother Pharmacol
|
2002
|
0.79
|
|
181
|
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
|
Curr Drug Metab
|
2011
|
0.78
|
|
182
|
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.
|
Eur J Cancer
|
2008
|
0.78
|
|
183
|
Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.
|
Clin Lung Cancer
|
2006
|
0.78
|
|
184
|
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
|
Clin Lung Cancer
|
2013
|
0.78
|
|
185
|
NUT rearrangement is uncommon in human thymic epithelial tumors.
|
J Thorac Oncol
|
2012
|
0.78
|
|
186
|
Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.
|
Clin Cancer Res
|
2006
|
0.78
|
|
187
|
The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy.
|
Anticancer Res
|
2006
|
0.77
|
|
188
|
18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer.
|
J Natl Cancer Inst
|
2007
|
0.77
|
|
189
|
Ongoing and future trials of biologic therapies in lung cancer.
|
Lung Cancer
|
2003
|
0.77
|
|
190
|
Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.
|
J Thorac Oncol
|
2012
|
0.77
|
|
191
|
Natural Killer T cells.
|
Lancet Oncol
|
2002
|
0.77
|
|
192
|
Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer.
|
Nat Rev Clin Oncol
|
2010
|
0.77
|
|
193
|
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
|
Mol Cancer Ther
|
2009
|
0.76
|
|
194
|
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
|
J Thorac Oncol
|
2013
|
0.76
|
|
195
|
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
|
Clin Cancer Res
|
2004
|
0.76
|
|
196
|
The role of talactoferrin alpha in the treatment of non-small cell lung cancer.
|
Expert Opin Biol Ther
|
2010
|
0.76
|
|
197
|
Challenges in cancer molecular targets and therapeutics.
|
Front Oncol
|
2011
|
0.75
|
|
198
|
Signal transduction modulators for cancer therapy: from promise to practice?
|
Oncologist
|
2003
|
0.75
|
|
199
|
Multiorgan autoimmune manifestations associated with thymoma.
|
J Thorac Oncol
|
2015
|
0.75
|
|
200
|
Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report.
|
Cases J
|
2009
|
0.75
|
|
201
|
The role of EGFR-TK inhibition in non-small cell lung cancer.
|
Onkologie
|
2005
|
0.75
|
|
202
|
Keynote comment: are large-scale cancer-genomics projects ready to use?
|
Lancet Oncol
|
2006
|
0.75
|
|
203
|
Antiangiogenic therapy in nonsmall cell lung cancer.
|
Curr Opin Oncol
|
2008
|
0.75
|
|
204
|
Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy.
|
Eur J Cancer
|
2006
|
0.75
|
|
205
|
Thymomas: the need for prospective studies.
|
J Thorac Oncol
|
2013
|
0.75
|
|
206
|
Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183.
|
Clin Cancer Res
|
2008
|
0.75
|
|
207
|
Antiangiogenesis induced tumor cavitation in lung cancer.
|
J Thorac Oncol
|
2009
|
0.75
|